The Evolution of Genomics Dealmaking
Executive Summary
SmithKline's 1993 $125 million alliance with Human Genome Sciences looked enormously overpriced at the time-and then quickly began to look more reasonable as prices for genomics deals skyrocketed. It was only with the addition of Takeda as a partnerthat the true possibilities of the SB/HGS alliance became evident: if both companies were to market the HGS database to partners, both could benefit.